These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 15078749)

  • 1. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
    Bousquet J; Wenzel S; Holgate S; Lumry W; Freeman P; Fox H
    Chest; 2004 Apr; 125(4):1378-86. PubMed ID: 15078749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
    Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab is effective in the long-term control of severe allergic asthma.
    Lanier BQ; Corren J; Lumry W; Liu J; Fowler-Taylor A; Gupta N
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):154-9. PubMed ID: 12952109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W; Gupta N; McAlary M; Fowler-Taylor A
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma.
    Buhl R; Hanf G; Solèr M; Bensch G; Wolfe J; Everhard F; Champain K; Fox H; Thirlwell J
    Eur Respir J; 2002 Nov; 20(5):1088-94. PubMed ID: 12449159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab improves asthma-related quality of life in children with allergic asthma.
    Lemanske RF; Nayak A; McAlary M; Everhard F; Fowler-Taylor A; Gupta N
    Pediatrics; 2002 Nov; 110(5):e55. PubMed ID: 12415061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on omalizumab in allergic asthma.
    Bang LM; Plosker GL
    BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.
    Buhl R; Solèr M; Matz J; Townley R; O'Brien J; Noga O; Champain K; Fox H; Thirlwell J; Della Cioppa G
    Eur Respir J; 2002 Jul; 20(1):73-8. PubMed ID: 12166585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.
    Corren J; Casale T; Deniz Y; Ashby M
    J Allergy Clin Immunol; 2003 Jan; 111(1):87-90. PubMed ID: 12532101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab: a review of its use in the management of allergic asthma.
    Bang LM; Plosker GL
    Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.